ORLANDO, Florida, May 16 / PRNewswire / - There have been four types of tumors at ASCO
The investigational new drug from Pfizer Inc, SUTENT/SU11248 (sunitinib malate) has doubled the survival rate ...
and reduced the growth and spread of tumors in a Phase III study in patients with gastrointestinal stromal tumors resistant to Gleevec (GIST). The promising results achieved in Phase II analysis were also observed in other tumor types, including metastatic carcinoma of the renal cell carcinoma (mRCC), metastatic breast cancer and neuroendocrine tumors, according to new data presented this week at the annual meeting American Society of Clinical Oncology (ASCO).
Showing posts with label Cancer experience. Show all posts
Showing posts with label Cancer experience. Show all posts
Sunday, July 10, 2011
Subscribe to:
Posts (Atom)